Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy

Pituitary

Volumn 14, Issue 3, 2011, Pages 199-207

  Berinder, Katarina ^a,b   Nyström, Thomas ^c   Höybye, Charlotte ^a,b   Hall, Kerstin ^a   Hulting, Anna Lena ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Dopamine agonist therapy; Euglycemic clamp; Hyperprolactinemia; Insulin resistance; LDL cholesterol

Indexed keywords

ADIPONECTIN; BROMOCRIPTINE; CABERGOLINE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROLACTIN; SOMATOMEDIN BINDING PROTEIN 1;

ADULT; ARTICLE; BODY FAT; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERPROLACTINEMIA; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADIPONECTIN; ADULT; BODY WEIGHT; BROMOCRIPTINE; DOPAMINE AGONISTS; FEMALE; HUMANS; IMMUNOASSAY; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; LIPIDS; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; PROLACTIN; PROLACTINOMA; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 80053920412     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-010-0277-9     Document Type: Article

References (33)

1. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW (1996) Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639-669 (Pubitemid 26425260)
2. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225-268 (Pubitemid 29117815)
3. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR (2006) Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 17:110-116
4. Landgraf R, Landraf-Leurs MM, Weissmann A, Horl R, von Werder K, Scriba PC (1977) Prolactin: a diabetogenic hormone. Diabetologia 13:99-104 (Pubitemid 8077629)
5. Johnston DG, Alberti KG, Nattrass M, Burrin JM, Blesa-Malpica G, Hall K, Hall R (1980) Hyperinsulinaemia in hyperprolacti-naemic women. Clin Endocrinol (Oxf) 13:361-368
6. Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28:138-142 (Pubitemid 15102183)
7. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366-370
8. Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003) Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 26:341-346 (Pubitemid 36763695)
9. Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, Haklar G, Akalin S (2003) Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 149:187-193 (Pubitemid 37120990)
10. Tuzcu A, Yalaki S, Arikan S, Gokalp D, Bahcec M, Tuzcu S (2009) Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary 12:330-334
11. Kamath V, Jones CN, Yip JC, Varasteh BB, Cincotta AH, Reaven GM, Chen YD (1997) Effects of a quick-release form of bro-mocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care 20:1697-1701 (Pubitemid 27463045)
12. Cincotta AH, Meier AH, Cincotta M Jr (1999) Bromocriptine improves glycemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 8:1683-1707 (Pubitemid 29460532)
13. Pelkonen R, Nikkila EA, Grahne B (1982) Serum lipids, post heparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 16:383-390 (Pubitemid 12188630)
14. Fahy U, Hopton MI, Hartog M, Bolton CH, Hull MG (1999) The lipoprotein profile of women with hyperprolactinemic amenor-rhoea. Hum Reprod 14:285-287 (Pubitemid 29097373)
15. Greenman Y, Tordjman K, Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 48:547-553 (Pubitemid 28252990)
16. Schmid C, Goede DL, Hauser RS, Brandle M (2006) Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolacti-noma. Swiss Med Wkly 136:254-258
17. Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocrip-tine. Eur J Endocrinol 147:77-84 (Pubitemid 34814743)
18. Delgrange E, Donckier J, Maiter D (1999) Hyperprolactinaemia as a reversible cause of weight gain in male patients? Clin Endocrinol (Oxf) 50:271 (Pubitemid 29100017)
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
20. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI (1985) Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 41:810-817 (Pubitemid 15092891)
21. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223 (Pubitemid 9249478)
22. Bang P, Eriksson U, Sara V, Wivall IL, Hall K (1991) Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 124:620-629
23. Hilding A, Hall K, Wivall-Helleryd IL, Saaf M, Melin AL, Thoren M (1999) Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab 84:2013-2019 (Pubitemid 30647027)
24. Povoa G, Roovete A, Hall K (1984) Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh) 107:563-570 (Pubitemid 15216173)
25. Lewitt MS, Hilding A, Brismar K, Efendic S, Ostenson CG, Hall K (2010) IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women. Eur J Endocrinol 163:233-242
26. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
27. Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O (2009) Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf) Dec 18. [Epub ahead of print]
28. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA (2000) Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23:1154-1161 (Pubitemid 30616805)
29. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA, Angelin B (1992) Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci USA 89:6983-6987
30. Dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR (2010) BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 17(9):1783-1788
31. Nilsson L, Binart N, Bohlooly YM, Bramnert M, Egecioglu E, Kindblom J, Kelly PA, Kopchick JJ, Ormandy CJ, Ling C, Billig H (2005) Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 331:1120-1126 (Pubitemid 40692475)
32. Brandebourg T, Hugo E, Ben-Jonathan N (2007) Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab 9:464-476 (Pubitemid 47018509)
33. Kotronen A, Lewitt M, Hall K, Brismar K, Yki-Jarvinen H (2008) Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab 93:4867-4872